Showing results (11-20 of 26) with videos related to
Sort By:
Pageof 3
Drugs Under Experimental and Clinical Research|January 1, 1990
Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1S R Burzynski, E Kubove, B BurzynskiDrugs Under Experimental and Clinical Research|January 1, 1986
Toxicology studies on antineoplaston AS2-1 injections in cancer patientsS R Burzynski, B Burzynski, M O MohabbatDrugs Under Experimental and Clinical Research|January 1, 1986
3-Phenylacetylamino-2,6-piperidinedione, a naturally-occurring peptide analogue with apparent antineoplastic activity, may bind to DNAA F Lehner, S R Burzynski, L B HendryDrugs Under Experimental and Clinical Research|January 1, 1987
In vitro cancer growth inhibition and animal toxicity studies of antineoplaston A3S S Lee, M O Mohabbat, S R BurzynskiDrugs Under Experimental and Clinical Research|January 1, 1986
Preclinical studies on antineoplaston AS2-1 and antineoplaston AS2-5S R Burzynski, M O Mohabbat, S S LeeDrugs Under Experimental and Clinical Research|January 1, 1987
Chemo-surveillance: a novel concept of the natural defence mechanism against cancerM C Liau, M Szopa, B Burzynski, et al.Drugs Under Experimental and Clinical Research|January 1, 1987
Quantitative assay of plasma and urinary peptides as an aid for the evaluation of cancer patients undergoing antineoplaston therapyM C Liau, M Szopa, B Burzynski, et al.Drugs Under Experimental and Clinical Research|January 1, 1995
The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptorsM Juszkiewicz, A Chodkowska, S R Burzynski, et al.Drugs Under Experimental and Clinical Research|January 1, 1987
Chemoprevention by antineoplaston A10 of benzo(a)pyrene-induced pulmonary neoplasiaB N Kampalath, M C Liau, B Burzynski, et al.Cancer Biochemistry Biophysics|January 1, 1979
Polypeptides that inhibit human breast cancer cell divisionP T Beall, B Szopa, S R Burzynski, et al.Pageof 3